Boston Scientific’s Taxus Liberte paclitaxel-eluting coronary stent system has received European CE Mark approval for use in patients with diabetes.

Boston Scientific’s  Taxus Liberte stent system has received European CE Mark approval.  The Taxus Liberte stent system is use for treatment of de novo and restenotic lesions or total occlusions in patients with coronary artery disease, angina, silent ischemia, acute myocardial infarction;  to improve luminal diameter and reduce restenosis within the stent and at the stent edges in native coronary arteries.

The Taxus Liberte stent system is also indicated for patients with concomitant diabetes mellitus as well as treatment of abrupt or threatened closure in patients with failed interventional therapy. The Taxus Liberte stent system is pending approval by the FDA and is not available for sale in the US.